A first case report of clinical response to targeted therapy in a patient with primary myoepithelial carcinoma of the lung harboring EGFR exon 19 deletion

Abstract

Background: Primary myoepithelial carcinoma of the lung is a rare subtype in lung cancer. Comprehensive molecular profiling of myoepithelial carcinoma of the lung is absent, neither was clinical evidence of targeted therapy available for this disease. Therefore, the optimal treatment regimen of this tumor needs to be established. Case presentation: Here we present a case of a 68-year-old patient with stage IVB primary myoepithelial carcinoma of the lung who harbored EGFR exon 19 deletion and KRAS mutation and underwent icotinib targeted therapy, achieving partial response (PR) with progression free survival (PFS) of 3 months. Conclusion: To our knowledge, this study describes the first documented case of primary myoepithelial carcinoma lung cancer patient harboring EGFR exon 19 deletion and KRAS mutation, and showed clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) treatment in this patient.

Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland‐type lung adenocarcinoma diagnosed due to esophageal stricture: A case report

“…It was found to be temporarily effective, but became less effective after three months. 8 In the case reported here, the primary lesion was not identified, and bronchoscopic findings led to a diagnosis of bronchogenic adenocarcinoma. Based on the treatment guidelines of lung cancer, CBDCA, PEM, and pembrolizumab were administered.…”

Clinical, laboratory, pathological, and radiological characteristics and prognosis of patients with pulmonary salivary gland-type tumors

“…If surgery or bronchoscopic intervention were not suitable, chemotherapy and/or radiation therapy were performed according to the patient's condition. For some special patients, tyrosine kinase inhibitor therapy (Macarenco et al 2022 ; Xie et al 2020 ) and immunotherapy (Gelsomino et al 2020 ) were also gradually developing. Therefore, there was no significant correlation between tumor type and prognosis, which might be affected by other factors.…”